Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: Biagio Ricciuti Clear advanced filters

  • The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from ICB alone or alongside chemotherapy is unclear. Here, the authors develop a machine-learning based approach to help guide individual treatment selection patients with mNSCLC.

    • Maliazurina B. Saad
    • Qasem Al-Tashi
    • Jia Wu
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-11

  • Alterations in the tumour suppressor genes STK11 and/or KEAP1 can identify patients with advanced non-small-cell lung cancer who are likely to benefit from combinations of PD-(L)1 and CTLA4 immune checkpoint inhibitors added to chemotherapy.

    • Ferdinandos Skoulidis
    • Haniel A. Araujo
    • John V. Heymach
    ResearchOpen Access
    Nature
    Volume: 635, P: 462-471

  • KRAS G12C mutant selective inhibitors targeting inactive state have been approved for use in non-small cell lung cancer (NSCLC). Here, using models derived from a patient with NSCLC who progressed on sotorasib (KRAS G12C inhibitor), the authors identify increased KRAS GTP loading as an adaptive resistance mechanism which could be targeted with KRAS G12C inhibitors selective to the GTP active state.

    • Marie-Julie Nokin
    • Alessia Mira
    • Chiara Ambrogio
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-18

  • Concurrent chemoradiation and durvalumab is standard of care for stage III non-small cell lung cancer, however, efficacy is variable. Here, the authors show PD-L1 tumor proportion score expression and increased tumor mutational burden are predictive of response and that early-onset pneumonitis leading to durvalumab discontinuation is associated with poor survival.

    • Joao V. Alessi
    • Biagio Ricciuti
    • Narek Shaverdian
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-12

  • Tyrosine kinases are promising therapeutic targets in multiple cancer types; however, the formation and selection of tyrosine kinase fusions are not fully understood. Here, the authors develop a genome-wide fusion sequencing platform and identify mechanisms and patterns of fusion formation that have implication for targeted therapy.

    • Taek-Chin Cheong
    • Ahram Jang
    • Roberto Chiarle
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-19

  • A genome-wide association study in large cohorts of patients with different types of cancer treated with immune checkpoint inhibitors identifies genetic variants associated with immune-related adverse events.

    • Stefan Groha
    • Sarah Abou Alaiwi
    • Alexander Gusev
    Research
    Nature Medicine
    Volume: 28, P: 2584-2591

  • Federated learning can be used to train medical AI models on sensitive personal data while preserving important privacy properties; however, the sensitive nature of the data makes it difficult to evaluate approaches reproducibly on real data. The MedPerf project presented by Karargyris et al. provides the tools and infrastructure to distribute models to healthcare facilities, such that they can be trained and evaluated in realistic settings.

    • Alexandros Karargyris
    • Renato Umeton
    • Peter Mattson
    ResearchOpen Access
    Nature Machine Intelligence
    Volume: 5, P: 799-810

  • Advances in technology have enabled the development of several novel antibody–drug conjugates (ADCs) with encouraging clinical activity in patients with advanced-stage solid tumours. Indications for these therapies are expanding rapidly to earlier lines of therapy. Nonetheless, the toxicities of these various agents are not trivial and can be fatal, even in patients with early stage disease. In this Review, the authors summarize the toxicities of ADCs in patients with solid tumours both as monotherapies and in combination with other agents and discuss various ongoing research efforts attempting to optimize the therapeutic index of these agents.

    • Paolo Tarantino
    • Biagio Ricciuti
    • Sara M. Tolaney
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 558-576